China Europe Fund and 100 billion fund manager Ge Lan purchased their own funds, which has become the screen news in today’s fund circle. Subsequently, Hua’an fund also announced that it plans to invest no less than 50 million self purchased partial share funds.
On January 26, China Europe Fund announced that the company would purchase 50 million yuan from China Europe medical health and China Europe medical innovation funds; Fund manager Glenn will also purchase 2 million yuan from the above two funds. The holding period is three years.
On the same day, Hua’an Fund announced that based on its confidence in the long-term, healthy and stable development of China’s capital market, the company will use its inherent funds to purchase the company’s partial share public offering fund from January 26 to February 25, with a total contribution of no less than 50 million yuan. The follow-up company will continue to subscribe for the partial share public offering fund of the company.
Since 2022, the market has fluctuated violently, and new development funds have been cold frequently. In this market, the large-scale self purchase of the public offering industry shows confidence in the market.
The joint efforts of Glenn and China Europe Fund also make it the focus of attention again today. In the four seasons report just disclosed, Ge Lan ranks among the 100 billion fund managers with a management scale of 110.339 billion yuan, surpassing Zhang Kun’s scale of 101.936 billion yuan in the same period, and temporarily ranks first in the management scale of active equity fund managers. On the other hand, as of January 25, China EU medical and health and China EU medical innovation fell by more than 10%, and “Gran, medical” also appeared on the microblog hot search list on Friday.
For this self purchase, China Europe Fund said that it was based on its confidence in the long-term healthy and stable development of China’s capital market and the company’s investment management ability. China Europe Fund also said that Glenn and the research team of China Europe Fund believe that the basis for the long-term growth of the pharmaceutical and biological industry has not changed, and the policy orientation is generally positive and stable. In the overall transformation period of the industry and the post epidemic era, enterprises pay more attention to cultivating internal skills and strengthening the establishment of hard power, and the upstream and downstream of the industrial chain are more perfect. Therefore, they are still optimistic about the long-term investment opportunities of the industry.
Obviously, a large wave of public offerings are supporting the market with real gold and silver to express confidence in the market. On the whole, the self purchase scale has gradually increased from the general level of 10 million.
Glenn and China Europe Fund purchased 52 million yuan
On January 26, China Europe Fund announced that the company would purchase a total of 50 million yuan of China Europe medical health fund and China Europe medical innovation fund with its own funds within 30 trading days from the date of the announcement, and hold them for more than three years. At the same time, fund manager Glenn will purchase a total of 2 million yuan from China Europe medical and health fund and China Europe medical innovation fund with his own funds within 30 trading days from the date of announcement, and hold them for more than three years.
China Europe Fund said that based on the confidence in the long-term healthy and stable development of China’s capital market and the company’s investment management ability, and in line with the principle of sharing risks and interests with the majority of investors, the company and fund managers made the decision to self purchase and hold relevant funds for a long time.
Recently, China Europe Fund disclosed the fund four seasons report managed by Ge Lan. By the end of 2021, the scale of Ge Lan’s public funds under management had reached 110.339 billion yuan, an increase of 13.338 billion yuan from 97.001 billion yuan in the previous quarter.
Among them, the scale of China EU health care at the end of the fourth quarter of 2021 was 77.505 billion yuan, an increase of 14.065 billion yuan compared with 63.44 billion yuan at the end of the previous quarter; The scale of China EU medical innovation at the end of the fourth quarter of 2021 was 13.094 billion yuan, an increase of 1.476 billion yuan compared with 11.618 billion yuan at the end of the previous quarter.
Since this year, the performance of the pharmaceutical sector has been divided. As of January 25, China EU medical and health and China EU medical innovation have fallen by more than 10%. Therefore, “Gran, medical” also appeared on the microblog hot search list on Friday.
However, China Europe Fund said that the above two funds, as industry theme funds, mainly focus on investment in the medical sector. Looking back on the past, the medical sector has experienced a rapid rise in the past two years and repeated disturbance of covid-19 epidemic, with large overall fluctuations. With the rapid adjustment in recent quarters, the long-term investment cost performance of individual stocks in the high-quality medical industry has further improved.
Looking forward to 2022, the fund manager Ge Lan and the China EU fund research team believe that the basis for the long-term growth of the pharmaceutical and biological industry has not changed, and the policy orientation is generally positive and stable. In the overall transformation period of the industry and the post epidemic era, enterprises pay more attention to cultivating internal skills and strengthening the establishment of hard power, and the upstream and downstream of the industrial chain are more perfect. Therefore, they are still optimistic about the long-term investment opportunities of the industry.
The reporter noted that although the short-term performance is greatly affected by the market, in the long run, the fund managed by Glenn has still achieved good returns. Taking China EU medical innovation as an example, the fund was established on February 28, 2019. The data show that the rate of return since its establishment has reached 102.07%. The other China Europe medical and health was established on September 29, 2016, with a yield of 197.16% in recent three years.
a large wave of public offering and self purchase is coming
In the fierce market shock, it is not only China Europe funds that choose self purchase to boost confidence.
On January 26, Hua’an fund also announced that from January 26 to February 25, it used its own funds to purchase the partial share public offering fund of the company, with a total contribution of no less than 50 million yuan.
On January 24, Bodao fund also purchased 10 million yuan from Bodao Jiafeng, Bodao Shengyan, Bodao consumption Zhihang, Bodao growth Zhihang and other funds.
In fact, previously affected by the market, many new development funds were frequently cold, and many companies also strengthened the confidence of investors through self purchase when issuing funds.
For example, when Xingquan Heheng fund was issued for three years, it purchased 50 million yuan from itself. When HSBC Jinxin issued the research selection of HSBC Jinxin, the fund company and the fund manager Lu Bin research team purchased a total of 13.2 million yuan. Cinda Aoyin also purchased 5 million yuan from itself when issuing Cinda Aoyin Zhiyuan for three years.
According to the reporter’s further statistics, the total amount of fund companies that have implemented self purchase since this year has reached 470 million yuan, of which the largest amount of self purchase is Nanfang fund, which purchased 200 million yuan when issuing Nanfang MSCI China A50 feeder fund.
A senior fund researcher told reporters that self purchase is mainly divided into two situations, one is the self purchase when the new fund is issued, and the other is the self purchase of existing old products. In his opinion, the self purchase of existing products, especially large self purchase, shows that the fund company has confidence in the future market.
At the time of self purchase, Bodao Fund said that although the market has weakened due to the disturbance of some uncertain factors, the current market has good investment value, mainly optimistic about the long-term and stable development prospect of China’s economy, and firmly believe that long-term investment is a reasonable way to share the value of the capital market. Especially when there is a “good price” in the market, we should adhere to it. Self purchase of self owned funds is also to share the interests with investors and strengthen everyone’s confidence.
However, whether the self purchase of the fund company indicates that the market has reached a phased low point, the above researchers said that at this time, the self purchase is only a performance of enhancing confidence, but also indicates that the fund company believes that it is more reasonable to buy at the current stage.
China Europe Fund also reminded investors that self purchase does not mean predicting the short-term trend. Individual investors need to formulate investment plans according to their own risk appetite and investment cycle. The fund has risks and needs to be cautious in investment.
China Europe Fund will buy 50 million from itself, and these fund companies also take out “real gold and silver” to buy their funds!
China Europe has just officially announced the purchase of 50 million medical theme fund. What is the signal from the top flow of Gelan’s purchase of 2 billion?
Give me a cardiotonic! China Europe Fund plans to purchase 50 million yuan from its two medical theme funds. Glenn plans to purchase 2 million yuan from itself
